- Home
- RANI
as 07-08-2024 4:00pm EST
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 129.7M | IPO Year: | 2021 |
| Target Price: | $11.83 | AVG Volume (30 days): | 50.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.82 - $8.75 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Rani Therapeutics Holdings Inc. (RANI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Imran Talat | RANI | Chief Executive Officer | Dec 6 '23 | Buy | $2.27 | 10,000 | $22,700.00 | 484,455 | SEC Form 4 |
| Imran Talat | RANI | Chief Executive Officer | Dec 4 '23 | Buy | $2.57 | 5,000 | $12,850.00 | 474,455 | SEC Form 4 |
| South Cone Investments Limited Partnership | RANI | 10% Owner | Nov 24 '23 | Buy | $2.01 | 5,265,165 | $10,582,981.65 | 12,131,554 | SEC Form 4 |
| Quiroga Cortes Isidoro Alfonso | RANI | 10% Owner | Nov 24 '23 | Sell | $2.01 | 5,265,165 | $10,582,981.65 | 8,400 | SEC Form 4 |
| Nanavaty Maulik | RANI | Director | Nov 16 '23 | Buy | $1.98 | 500 | $990.00 | 500 | SEC Form 4 |
Latest Rani Therapeutics Holdings Inc. News
RANI Breaking Stock News: Dive into RANI Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
10 days ago
RANI: GLP-2 Deal Announced
MT Newswires
14 days ago
Rani Therapeutics Partners With ProGen for Oral Obesity Treatment Development; Shares Rise
GlobeNewswire
14 days ago
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
MT Newswires
24 days ago
Maxim Starts Coverage on Rani Therapeutics With Buy Rating, $15 Price Target
MT Newswires
2 months ago
UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating
GlobeNewswire
2 months ago
Rani Therapeutics to Participate in May Investor Conferences
GlobeNewswire
2 months ago
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
Zacks Small Cap Research
2 months ago
RANI: 1Q:24 Results
Share on Social Networks:
Disclaimer
The information presented on this page, "RANI Rani Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.